Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests

Executive Summary

Indication-specific pricing could address 'tension' between initial pricing of Ocaliva for orphan condition and later use in large patient population, according to expert roundtable convened by Institute for Clinical and Economic Review.

You may also be interested in...



ICER Determines OCA’s Benefit In NASH Might Support Limited Approval

The cost-effectiveness watchdog group sees the fibrosis benefit with Intercept’s obeticholic acid as supporting use in sicker NASH patients, but its overall risk-benefit ratio doesn’t merit broader use.

Orphan Drug Pricing Heading To Negotiating Table in US?

The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS118875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel